MAP Pharmaceuticals (MAPP) Phase 3 Trial of LEVADEX Migraine Product Candidate Meets All Four Primary Endpoints
More News related to MAPP
- MAP Pharma. (MAPP) Secures $60M Equity Financing Facility with Azimuth Opportunity
- MAP Pharmaceuticals Secures $60 Million Committed Equity Financing Facility
- MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
- MAP Pharmaceuticals Reports Third Quarter of 2009 Financial Results
- MAP Pharmaceuticals Completes Interim Safety Review of LEVADEX(TM) Open-Label Safety Extension in More Than 400 Patients
MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the efficacy portion of its first Phase 3 clinical trial evaluating its novel LEVADEX(TM) orally inhaled migraine therapy met all four primary endpoints. Additional endpoints showed that LEVADEX provided rapid and sustained pain relief for up to 48 hours after dosing.
Related Categories
Corporate NewsFDA
Stocks Mentioned
+0.23Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
